The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Antisense therapy for cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 1×
“More recently, the use of double-stranded 21-nucleotide siRNAs that specifically suppress the expression of homologous genes has been describe”
BackgroundDarnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“Following specific receptor stimulation and dimerization, activation of the Janus tyrosine kinases or SRC family members results in the phosphorylation and activation of STAT family member”
BackgroundInsulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Bcl-2 and the regulation of programmed cell death
Reed, J. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.1.1 · Cited by 2,305
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“Since then, an abundance of studies have presented strong evidence that persistent STAT3 signalling activity participates in malignant transformation, resulting in the increased expression of genes associated with proliferation, cell survival, angiogenesi”
BackgroundTherapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
X-linked IAP is a direct inhibitor of cell-death proteases
Deveraux, Q. L., Takahashi, R., Salvesen, G. S., & Reed, J. C. (1997) · Nature · doi:10.1038/40901 · Cited by 1,955
Control of apoptosis and mitotic spindle checkpoint by survivin
Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., & Altieri, D. C. (1998) · Nature · doi:10.1038/25141 · Cited by 1,870
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Cited by
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
RetractedPromoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
MicroRNAs — the micro steering wheel of tumour metastases
Nicoloso, M. S., Spizzo, R., Shimizu, M., Rossi, S., & Calin, G. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2619 · Cited by 749
Lotze, M. T., Zeh, H. J., Rubartelli, A., Sparvero, L. J., Amoscato, A. A., Washburn, N. R., DeVera, M. E., Liang, X., Tör, M., & Billiar, T. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00579.x · Cited by 641
Polyvalent DNA Nanoparticle Conjugates Stabilize Nucleic Acids
Seferos, D. S., Prigodich, A. E., Giljohann, D. A., Patel, P. C., & Mirkin, C. A. (2009) · Nano Letters · doi:10.1021/nl802958f · Cited by 551
Novel therapies emerging in oncology to target the TGF‐β pathway
Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J., & Driscoll, J. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01053-x · Cited by 453
ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION
Chan, J. H., Lim, S., & Wong, W. F. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04403.x · Cited by 430
Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?
Weiler, J., Hunziker, J., & Hall, J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302654 · Cited by 371
Matsubara, H., Takeuchi, T., Nishikawa, E., Yanagisawa, K., Hayashita, Y., Ebi, H., Yamada, H., Suzuki, M., Nagino, M., Nimura, Y., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210425 · Cited by 369
Nanomedicine in the management of microbial infection – Overview and perspectives
Zhu, X., Radovic-Moreno, A. F., Wu, J., Langer, R., & Shi, J. (2014) · Nano Today · doi:10.1016/j.nantod.2014.06.003 · Cited by 362
Protein Kinase CK2 in Health and Disease: CK2: A key player in cancer biology
Trembley, J. H., Wang, G., Unger, G., Slaton, J., & Ahmed, K. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-9154-y · Cited by 354
Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer
Shannan, B., Seifert, M., Leskov, K., Willis, J., Boothman, D., Tilgen, W., & Reichrath, J. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401779 · Cited by 318
Cell-Penetrating Peptides—Mechanisms of Cellular Uptake and Generation of Delivery Systems
Trabulo, S., Cardoso, A. L., Mano, M., & De Lima, M. C. P. (2010) · Pharmaceuticals · doi:10.3390/ph3040961 · Cited by 290
Chemical modification: the key to clinical application of RNA interference?
Corey, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33483 · Cited by 285
Emerging Role of MicroRNAs in Cardiovascular Biology
Latronico, M. V. G., Catalucci, D., & Condorelli, G. (2007) · Circulation Research · doi:10.1161/circresaha.107.163147 · Cited by 284
Alternative splicing: an emerging topic in molecular and clinical oncology
Pajares, M. J., Ezponda, T., Catena, R., Calvo, A., Pio, R., & Montuenga, L. M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70104-3 · Cited by 267
MicroRNA and cancer: Current status and prospective
Wu, W., Sun, M., Zou, G., & Chen, J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22454 · Cited by 266
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0510 · Cited by 245
Moreira, D., Adamus, T., Zhao, X., Su, Y.-L., Zhang, Z., White, S. V., Swiderski, P., Lu, X., DePinho, R. A., Pal, S. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1277 · Cited by 80
Metadata
- Authors
- Gleave, M. E., & Monia, B. P.
- Venue
- Nature Reviews Cancer
- Published
- 2005-05-20
- Volume
- 5
- Issue
- 6
- Pages
- 468-479
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1990507217
- Cited by
- 384
- References
- 143
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.